Sub-50 fs, 0.5 W average power Nd-doped fiber amplifier at 920 nm
Optics Letters · 01.01.2024 · 49 (1) · 57
DOI: 10.1364/ol.509507 ↗Kurz gefasst
Fachartikel in der Zeitschrift Optics Letters, online erschienen am 19.12.2023. Verfasst von Ti-Jian Li und 5 weiteren Autor:innen. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Basic and Applied Basic Research Foundation of Guangdong Province.
Abstract (Originalsprache)
We develop an all polarization-maintaining (PM) 920 nm Nd-doped fiber amplifier delivering a train of pulses with ∼0.53 W average power and sub-50 fs duration. The sub-50 fs pulse benefits from the pre-chirping management method that allows for over 60 nm broadening spectrum without pulse breaking in the amplification stage. By virtue of the short pulse duration, the pulse peak power can reach to ∼0.31 MW in spite of the moderate average power. These results represent a key step in developing high-peak-power pulse Nd-doped fiber laser systems at 920 nm, which will find important applications in fields such as biomedical imaging, ultrafast optical spectroscopy, and excitation of quantum-dot single photon sources.
Förderung
- National Natural Science Foundation of China
- Basic and Applied Basic Research Foundation of Guangdong Province
Zitieren
APA
Li, T. J., Sun, H., Liu, M., Luo, A. P., Xu, W. C., & Luo, Z. C. (2024). Sub-50 fs, 0.5 W average power Nd-doped fiber amplifier at 920 nm. Optics Letters, 49(1), 57. https://doi.org/10.1364/ol.509507
Vancouver
Li TJ, Sun H, Liu M, Luo AP, Xu WC, Luo ZC. Sub-50 fs, 0.5 W average power Nd-doped fiber amplifier at 920 nm. Optics Letters. 2024;49(1):57. doi:10.1364/ol.509507
BibTeX
@article{Li2024,
author = {Li, Ti-Jian and Sun, He and Liu, Meng and Luo, Ai-Ping and Xu, Wen-Cheng and Luo, Zhi-Chao},
title = {Sub-50 fs, 0.5 W average power Nd-doped fiber amplifier at 920 nm},
journal = {Optics Letters},
year = {2024},
volume = {49},
number = {1},
pages = {57},
doi = {10.1364/ol.509507}
}
EUVIMED